Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

Some small IPOs are tentatively scheduled for the short holiday week ahead. Space and defense contractor Karman Holdings (KRMN) priced its upsized IPO above the range to raise $506 million at a $2.9 ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Maze has two kidney disease drugs currently in the clinical, and the biotech was able raise $140 million in IPO cash to support those programs and more in its pipeline. Maze’s shares now trade ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Aardvark Therapeutics will debut on Nasdaq at $16/share, to raise $94M for hunger-focused metabolic disease treatments. ARD-101 Phase 3 data expected early 2025.